Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Closed Good Friday 04-17 16:00:00 EDT

1.22

-0.04

-3.17%

盘后1.22

+0.000.00%

19:12 EDT

High1.27	Low1.19	Vol73.59K
Open1.24	D1 Closing1.26	Amplitude6.35%
Mkt Cap23.77M	Tradable Cap19.12M	Total Shares19.49M
T/O90.11K	T/O Rate0.47%	Tradable Shares15.67M
P/B2.55	ROE-3159.09%	EPS-2.31
52wk High20.00	52wk Low1.11	P/E-0.53
Dividend0.00	Div.Yield0.00	ROA-138.26%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":1.22,"timestamp":1744920000000,"preClose":1.26,"halted":0,"volume":73587,"hourTrading":{"tag":"盘后","latestPrice":1.22,"preClose":1.22,"latestTime":"19:12 EDT","volume":7,"amount":8.44,"timestamp":1744931578169},"delay":0,"floatShares":15671273,"shares":19486231,"eps":-2.306109,"marketStatus":"Closed Good Friday","change":-0.04,"latestTime":"04-17 16:00:00 EDT","open":1.24,"high":1.27,"low":1.19,"amount":90113.83810169999,"amplitude":0.063492,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.306109,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":1.26,"preHourTrading":{"tag":"盘前","latestPrice":1.2599,"preClose":1.26,"latestTime":"08:00 EDT","volume":2,"amount":2.5198,"timestamp":1744891202190},"postHourTrading":{"tag":"盘后","latestPrice":1.22,"preClose":1.22,"latestTime":"19:12 EDT","volume":7,"amount":8.44,"timestamp":1744931578169},"volumeRatio":0.5162905830258567,"impliedVol":0.9969,"impliedVolPercentile":0.2351},"requestUrl":"/m/hq/s/ANVS","defaultTab":"news","newsList":[{"id":"2522306105","title":"Annovis Bio Gets NYSE Noncompliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2522306105","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522306105?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 05:36","pubTimestamp":1743111391,"startTime":"0","endTime":"0","summary":"Annovis Bio  said Thursday it has received a noncompliance notice from the New York Stock Exchange for market capitalization and stockholders' equity both below $50 million for 30 consecutive days.It has notified the NYSE of its intention to submit a plan within 45 days detailing how it plans to regain listing compliance in the next 18 months, the company said in a statement.The notice does not impact the company's operations or reporting obligations with the US Securities and Exchange Commission.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYSE","BK4139","ANVS"],"gpt_icon":0},{"id":"2522753210","title":"Annovis Bio receives noncompliance notification from NYSE","url":"https://stock-news.laohu8.com/highlight/detail?id=2522753210","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522753210?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:56","pubTimestamp":1743108975,"startTime":"0","endTime":"0","summary":"Annovis Bio (ANVS) announced that it received notice from the NYSE that it is no longer in compliance with the NYSE continued listing standards set...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-receives-noncompliance-notification-from-nyse?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-receives-noncompliance-notification-from-nyse?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NYSE","ANVS","BK4139"],"gpt_icon":0},{"id":"2522532106","title":"Annovis Bio Faces NYSE Non-Compliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2522532106","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522532106?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:55","pubTimestamp":1743108941,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) has provided an announcement. On March 26, 2025, Annovis Bio, Inc. received a notice from the New York Stock Exchange (NYSE...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-faces-nyse-non-compliance-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-faces-nyse-non-compliance-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NYSE","BK4139","ANVS"],"gpt_icon":0},{"id":"2522708531","title":"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the Nyse","url":"https://stock-news.laohu8.com/highlight/detail?id=2522708531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522708531?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:30","pubTimestamp":1743107400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA6ZD37G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2522344545","title":"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE","url":"https://stock-news.laohu8.com/highlight/detail?id=2522344545","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522344545?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:30","pubTimestamp":1743107400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March 27, 2025  -- Annovis Bio, Inc.  , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease  and Parkinson’s disease , today announced that on March 26, 2025, it received notice  from the New York Stock Exchange  that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders’ equity was less than $50 million.The Notice does not affect the Company’s business operations or its reporting obligations with the Securities and Exchange Commission, and it does not conflict with or cause an event of default under any of the Company’s material debt or other agreements.Cautionary Note Regarding Forward-Looking StatementsThis press release contains, and oral sta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-bio-inc-receives-continued-203000438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169589451.USD","BK4124","ANVS","NYSE","BK4023","SMP","LU1169590202.USD","BK4139","PD"],"gpt_icon":0},{"id":"2522022409","title":"Annovis Bio Inc : Maxim Group Cuts Target Price to $8 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022409?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:04","pubTimestamp":1742904246,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q8160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2522022508","title":"Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022508","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022508?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March 25, 2025  -- Annovis Bio Inc.  , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease  and Parkinson's disease , today announced its participation in the AD/PD2025 taking place April 1-5 in Vienna.\"We are at a pivotal moment in our company’s journey as we have entered the late clinical stages for both Alzheimer’s and Parkinson’s. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications,” commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. “At this meeting, we will present comprehensive data from our latest Phase 3 PD and Phase 2/3 AD studies. For Parkinson’s, we will take a deeper look into the cognitive response, while for Alzheimer’s, we will dive into the advantages of buntanetap for APOE4 carriers, addressing a pressing challenge in existing AD therapies.\". Annovis will give two pre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-attend-ad-pd-2025-120000604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD","LU1169590202.USD","ANVS","BK4139","BK4023","LU1169589451.USD"],"gpt_icon":0},{"id":"2521766137","title":"Reported Friday, Annovis Bio Q4 2024 GAAP EPS $(0.43) Misses $(0.40) Estimate, Cash $10.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2521766137","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521766137?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 14:50","pubTimestamp":1742799010,"startTime":"0","endTime":"0","summary":"Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.40) by 7.5 percent. This is a 81.55 percent increase over losses of $(2.33) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44452140/reported-friday-annovis-bio-q4-2024-gaap-eps-0-43-misses-0-40-estimate-cash-10-6m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS"],"gpt_icon":0},{"id":"2521572922","title":"Annovis Bio reports Q4 EPS (43c) vs. ($2.24) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2521572922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521572922?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 05:10","pubTimestamp":1742591410,"startTime":"0","endTime":"0","summary":"Annovis’ cash and cash equivalents totaled $10.6M as of December 31, 2024, compared to $5.8M as of December 31, 2023. The company estimates that it...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-reports-q4-eps-43c-vs-2-24-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-reports-q4-eps-43c-vs-2-24-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANVS"],"gpt_icon":0},{"id":"2521325758","title":"Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521325758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521325758?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 05:05","pubTimestamp":1742591130,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nTUA6DVJXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2521125755","title":"Press Release: Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521125755","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521125755?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 05:05","pubTimestamp":1742591100,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March 21, 2025  -- Annovis Bio Inc.  , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease  and Parkinson's disease , today provided corporate updates and fourth quarter/full year 2024 financial results.\"The last year was filled with extraordinary achievements for our company, and we are pleased with our continued momentum into 2025,\" said Maria Maccecchini, Ph.D., Founder and CEO of Annovis. \"We are deeply grateful to everyone who has supported and believed in our mission. As we move ahead, our focus remains on generating robust data for buntanetap and advancing its path to the patients who need it most.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU0348723411.USD","LU0345774631.USD","LU0205193047.USD","LU1169589451.USD","ANVS","LU0205194284.USD","DLB","LU0240877869.USD","LU0240878834.USD","LU0345774391.USD","PD","BK4139","LU1169590202.USD","BK4097"],"gpt_icon":0},{"id":"2518748268","title":"Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2518748268","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518748268?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 20:00","pubTimestamp":1741694400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March  11, 2025  (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) (\"Annovis\"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative dise","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3040492/0/en/Annovis-Joins-Experts-at-Drug-Development-Summit-to-Redefine-Parkinson-s-Treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","SMMF","BK4023","BK4211","LU1169589451.USD","PD","BK4139","ANVS"],"gpt_icon":0},{"id":"2512102428","title":"Annovis to Host Patients’ Live Forum on February 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512102428","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512102428?lang=en_us&edition=full_marsco","pubTime":"2025-02-19 21:30","pubTimestamp":1739971800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Feb.  19, 2025  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a clinical-stage drug platform company developing novel therapies for neurodege","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/19/3028769/0/en/Annovis-to-Host-Patients-Live-Forum-on-February-27-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0264410563.USD","LU0164881194.USD","PD","BK4218","LU0531971678.HKD","BK4179","LU0143863784.USD","BK4023","BK4207","BK4585","LU1169590202.USD","LU1169589451.USD","LU0048575426.USD","SG9999004220.SGD","BK4588","LU0143863198.USD","IE00BYTNYM70.SGD","LU1102505762.USD","LU0181495838.USD","LU1102505929.USD","LU0828237940.HKD","IE00B7N09G41.SGD","ANVS","BK4139","LU1481012133.USD","FET","HST","BK4535","LU0251143458.SGD","LU0823038988.USD","IE00B0JY6M65.USD","LU0823039010.USD","LU1868837722.USD","LU1868838027.USD","LU0066902890.USD","IBN","LU1868837565.USD","LU0261950470.USD","BK4181","BK4523","BK4548"],"gpt_icon":0},{"id":"2510065856","title":"Annovis Bio Cut to Hold From Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2510065856","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510065856?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 20:17","pubTimestamp":1739189820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2025 07:17 ET (12:17 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2509803743","title":"Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2509803743","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509803743?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 21:00","pubTimestamp":1738933200,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Feb. 07, 2025  -- via IBN – Annovis Bio Inc.  , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease  and Parkinson's disease , today announced that its CEO, Maria Maccecchini, Ph.D., will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference.Attendees can access the live presentation through the conference's virtual platform.Dr. Maccecchini will discuss the Company’s latest advancements, highlighting the progress of the pivotal Phase 3 trial in early AD and strategic initiatives toward a New Drug Application  for buntanetap as both a symptomatic and potentially disease-modifying treatment.Oppenheimer's Annual Healthcare Life Sciences Conference is a premier event that brings together leading companies and investors in the healthcare and life sciences sectors. The conference features presentations from industry executives, providing insights into current trends, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-present-oppenheimers-35th-annual-130000285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4127","LU1102505762.USD","IBN","LU1868837565.USD","OPY","BK4139","BK4137","LU0823039010.USD","BK4207","LU1868838027.USD","LU0251143458.SGD","PD","BK4548","HCSG","LU1481012133.USD","BK4585","ANVS","LU0823038988.USD","LU0828237940.HKD","LU1169590202.USD","LU0264410563.USD","LU1169589451.USD","LU0181495838.USD","LU1868837722.USD","BK4023","LU0164881194.USD","BK4588","LU0261950470.USD","LU0143863198.USD","LU0531971678.HKD","IE00B0JY6M65.USD","BK4523","LU0143863784.USD","LU0048575426.USD","SG9999004220.SGD","IE00B7N09G41.SGD","LU1102505929.USD","BK4535","IE00BYTNYM70.SGD","LU0066902890.USD"],"gpt_icon":0},{"id":"2509595275","title":"Annovis Bio announces first patients entered Phase 3 study of buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2509595275","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509595275?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 21:20","pubTimestamp":1738848041,"startTime":"0","endTime":"0","summary":"Annovis Bio  announced that the first two patients have been entered into the Phase 3 study evaluating buntanetap in early AD. “The launch of our highly anticipated AD study is a significant milestone in advancing buntanetap toward market approval and addressing the unmet medical need of millions of patients. Our previous trials have delivered compelling results, and we have meticulously designed a comprehensive protocol to evaluate both the symptomatic and potential disease-modifying effects of our drug candidate,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis.Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  Your Smart Portfolio. Annovis Bio announces pricing of $21M offering of stock, warrants. Annovis Bio announces FDA acceptance of protocol for Phase 3 AD study. Annovis Bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/annovis-bio-announces-first-patients-132041350.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-bio-announces-first-patients-132041350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2509236983","title":"Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2509236983","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509236983?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 00:06","pubTimestamp":1738771584,"startTime":"0","endTime":"0","summary":"Annovis Bio  said Wednesday it enrolled the first two participants in its phase 3 trial of buntanetap for early Alzheimer's disease.The trial will evaluate the safety and efficacy of a daily dose of buntanetap, with treatment lasting for 18 months.The study includes a 6-month assessment of symptomatic effects followed by a 12-month evaluation of potential disease-modifying effects. Annovis said it plans to enroll more than 750 patients across about 100 sites in the US.The US Food and Drug Administration approved the Phase 3 protocol for the trial in January, the company added.Shares of Annovis were down 1.4% in recent trading.Price: 3.10, Change: -0.04, Percent Change: -1.43","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2509886286","title":"Annovis Bio Launches Phase 3 Alzheimer’s Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2509886286","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509886286?lang=en_us&edition=full_marsco","pubTime":"2025-02-05 21:28","pubTimestamp":1738762117,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) just unveiled an announcement. On February 5, 2025, Annovis Bio Inc. announced the commencement of its pivotal Phase 3 stud...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-launches-phase-3-alzheimers-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-launches-phase-3-alzheimers-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2509833742","title":"Annovis Announces First Patients Entered Into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2509833742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509833742?lang=en_us&edition=full_marsco","pubTime":"2025-02-05 21:00","pubTimestamp":1738760405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nTUA2SRKML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2509285314","title":"Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2509285314","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509285314?lang=en_us&edition=full_marsco","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Feb.  05, 2025  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a late-stage clinical drug platform company pioneering transformative therapies ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3021101/0/en/Annovis-Announces-First-Patients-Entered-into-Pivotal-Phase-3-Study-of-Buntanetap-for-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0264410563.USD","LU0164881194.USD","LU1169589451.USD","ANVS","BK4585","LU1169590202.USD","LU0048575426.USD","LU1102505929.USD","BK4523","LU0143863198.USD","PD","LU1868838027.USD","LU1481012133.USD","BK4548","LU0261950470.USD","LU0251143458.SGD","IE00B7N09G41.SGD","LU0823038988.USD","BK4588","LU0066902890.USD","LU0531971678.HKD","LU0143863784.USD","LU0181495838.USD","LU1102505762.USD","SG9999004220.SGD","BK4207","BK4535","LU1868837565.USD","LU0823039010.USD","IE00B0JY6M65.USD","LU0828237940.HKD","BK4023","IBN","BK4139","LU1868837722.USD","IE00BYTNYM70.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.0469},{"period":"1month","weight":-0.3146},{"period":"3month","weight":-0.7565},{"period":"6month","weight":-0.8675},{"period":"1year","weight":-0.8643},{"period":"ytd","weight":-0.7575}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.00486},{"month":2,"riseRate":0.333333,"avgChangeRate":0.070008},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.037484},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.164852},{"month":5,"riseRate":0.6,"avgChangeRate":0.247553},{"month":6,"riseRate":0.6,"avgChangeRate":0.216567},{"month":7,"riseRate":0.6,"avgChangeRate":0.066217},{"month":8,"riseRate":0.4,"avgChangeRate":-0.05366},{"month":9,"riseRate":0.4,"avgChangeRate":-0.049402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.090551},{"month":11,"riseRate":0.6,"avgChangeRate":0.036162},{"month":12,"riseRate":0.4,"avgChangeRate":0.213127}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction